Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$31.18 +2.6%	$29.99	$21.97 ▼ $32.94	$1.30B	1.62	338,953 shs	186,282 shs
EYE National Vision	$25.48 +2.0%	$22.26	$9.56 ▼ $25.65	$1.98B	1.27	1.92 million shs	1.44 million shs
INMD InMode	$14.93 +3.6%	$14.37	$13.14 ▼ $19.85	$910.84M	1.95	1.20 million shs	1.38 million shs
SNWV Sanuwave Health	$36.77 +4.0%	$31.75	$5.17 ▼ $39.83	$302.93M	1.24	109,799 shs	35,670 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	-0.50%	-2.44%	+0.59%	+28.24%	+10.95%
EYE National Vision	-1.26%	-1.07%	+9.22%	+112.66%	+89.25%
INMD InMode	+3.22%	+1.12%	+8.51%	-7.51%	-18.82%
SNWV Sanuwave Health	-7.73%	+6.25%	+4.96%	+24.17%	+3,534,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AORT Artivion	2.938 of 5 stars	1.6	5.0	0.0	0.0	3.4	2.5	1.9
EYE National Vision	2.7817 of 5 stars	2.3	2.0	0.0	3.3	2.7	0.8	0.0
INMD InMode	3.5018 of 5 stars	3.1	4.0	0.0	0.0	3.1	1.7	1.9
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AORT Artivion	3.17	Buy	$32.40	3.91% Upside
EYE National Vision	2.56	Moderate Buy	$23.00	-9.73% Downside
INMD InMode	2.13	Hold	$18.54	24.19% Upside
SNWV Sanuwave Health	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SNWV, EYE, INMD, and AORT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2025	EYE National Vision	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $24.00
7/11/2025	INMD InMode	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$15.00
7/8/2025	EYE National Vision	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/8/2025	EYE National Vision	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$30.00
7/8/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$17.00 ➝ $30.00
6/18/2025	EYE National Vision	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
6/17/2025	AORT Artivion	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/19/2025	EYE National Vision	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Perform ➝ Market Perform	$13.00 ➝ $19.00
5/12/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $17.00
5/9/2025	EYE National Vision	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$13.00 ➝ $17.00
5/9/2025	EYE National Vision	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$13.00 ➝ $21.00

(Data available from 7/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AORT Artivion	$388.54M	3.43	$0.86 per share	36.44	$6.59 per share	4.73
EYE National Vision	$1.82B	1.10	$1.67 per share	15.28	$10.37 per share	2.46
INMD InMode	$392.41M	2.40	$1.89 per share	7.90	$10.12 per share	1.48
SNWV Sanuwave Health	$32.63M	9.66	N/A	N/A	($1.49) per share	-24.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AORT Artivion	-$13.36M	-$0.50	N/A	62.36	N/A	-5.49%	3.63%	1.34%	8/6/2025 (Estimated)
EYE National Vision	-$28.50M	-$0.33	N/A	94.37	3.66	-1.40%	3.44%	1.40%	8/6/2025 (Estimated)
INMD InMode	$181.27M	$2.33	6.41	8.20	N/A	44.79%	17.17%	15.20%	7/30/2025 (Estimated)
SNWV Sanuwave Health	-$31.37M	-$4.56	N/A	∞	N/A	-89.86%	N/A	-145.76%	N/A

Latest SNWV, EYE, INMD, and AORT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AORT Artivion	$0.11	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	EYE National Vision	$0.12	N/A	N/A	N/A	$469.21 million	N/A
7/30/2025	Q2 2025	INMD InMode	$0.50	N/A	N/A	N/A	$98.45 million	N/A
5/9/2025	Q1 2025	SNWV Sanuwave Health	N/A	-$0.66	N/A	-$0.66	N/A	$9.34 million
5/7/2025	Q1 2025	EYE National Vision	$0.32	$0.34	+$0.02	$0.18	$510.30 million	$510.32 million
5/5/2025	Q1 2025	AORT Artivion	$0.12	$0.06	-$0.06	-$0.01	$94.81 million	$98.98 million
4/28/2025	Q1 2025	INMD InMode	$0.45	$0.31	-$0.14	$0.26	$82.21 million	$77.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AORT Artivion	N/A	N/A	N/A	N/A	N/A
EYE National Vision	N/A	N/A	N/A	N/A	N/A
INMD InMode	N/A	N/A	N/A	N/A	N/A
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AORT Artivion	1.08	5.53	3.95
EYE National Vision	0.29	0.54	0.35
INMD InMode	N/A	8.73	7.86
SNWV Sanuwave Health	N/A	0.40	0.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AORT Artivion	86.37%
EYE National Vision	N/A
INMD InMode	68.04%
SNWV Sanuwave Health	42.53%

Insider Ownership

Company	Insider Ownership
AORT Artivion	7.60%
EYE National Vision	2.70%
INMD InMode	6.92%
SNWV Sanuwave Health	14.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AORT Artivion	1,600	42.70 million	39.46 million	Optionable
EYE National Vision	13,411	79.05 million	76.92 million	Optionable
INMD InMode	480	63.21 million	58.84 million	Optionable
SNWV Sanuwave Health	40	8.57 million	7.29 million	N/A

SNWV, EYE, INMD, and AORT Headlines

Recent News About These Companies

Sanuwave Health to Present at Canaccord Genuity Growth Conference

July 22 at 4:05 PM | globenewswire.com

Sanuwave: High Growth Wound Care Tech Primed For A Breakout

June 11, 2025 | seekingalpha.com

Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations

June 3, 2025 | globenewswire.com

SANUWAVE Health, Inc. (SNWV): A Bull Case Theory

May 29, 2025 | insidermonkey.com

Sanuwave Health Appoints Greg Bazar to Board of Directors

May 28, 2025 | globenewswire.com

Sanuwave Health Selected for Inclusion in Russell 2000Â® Index

May 28, 2025 | globenewswire.com

Insider Selling: SANUWAVE Health, Inc. (NASDAQ:SNWV) Insider Sells 3,639 Shares of Stock

May 17, 2025 | insidertrades.com

SANUWAVE Health, Inc. (SNWV) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Sanuwave Announces Q1 FY2025 Financial Results

May 9, 2025 | globenewswire.com

Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial Results

May 5, 2025 | globenewswire.com

SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)

April 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
By Dan Schmidt | July 2, 2025
View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside
By Ryan Hasson | July 1, 2025
View Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside
CrowdStrike Eyes Breakout as Cyber Threats Boost Demand
By Chris Markoch | June 24, 2025
View CrowdStrike Eyes Breakout as Cyber Threats Boost Demand
3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
By Chris Markoch | July 14, 2025
View 3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge
By Chris Markoch | June 27, 2025
View Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge

SNWV, EYE, INMD, and AORT Company Descriptions

Artivion NYSE:AORT

$31.18 +0.78 (+2.57%)

Closing price 03:59 PM Eastern

Extended Trading

$31.24 +0.07 (+0.21%)

As of 05:48 PM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

National Vision NASDAQ:EYE

$25.48 +0.49 (+1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$25.36 -0.13 (-0.49%)

As of 05:08 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

InMode NASDAQ:INMD

$14.93 +0.52 (+3.61%)

Closing price 04:00 PM Eastern

Extended Trading

$14.88 -0.05 (-0.31%)

As of 07:52 PM Eastern

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Sanuwave Health NASDAQ:SNWV

$36.77 +1.42 (+4.02%)

As of 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time